We show here that FOXK2 regulates FOXO3a to modulate drug sensitivity and that deregulation of expression and activity of FOXK2 confers paclitaxel and epirubicin resistance and associates with a poor clinical outcome in breast carcinoma patients. Here, FOXK2 is linked to breast carcinoma.